Contract Win
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your IXI notes
IXICO plc (AIM: IXI), the precision analytics company delivering intelligent insights in neuroscience, is pleased to announce that it has been contracted by a top five CRO on behalf of a new pharma client to provide its imaging biomarker services for a Phase 3 clinical trial for patients with a type of Parkinsonian disorder. The trial is due to run for just under 5 years and is worth in excess of £1m.
Giulio Cerroni, Chief Executive Officer of IXICO, commented:
"Following the new contract win announced on 23rd May in Alzheimer's Disease, we are delighted to be announcing the award of a contract from a new client to support the development of a promising treatment targeting a Parkinsonian disorder. We are pleased that our expertise in providing imaging analysis and radiological reads across clinical trials for a broadening range of neurodegenerative disorders, is increasingly recognised across the drug development industry and continues to attract new Sponsors seeking these expert services."
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.